CEL-SCI (NYSE:CVM) Research Coverage Started at StockNews.com

by · The Cerbat Gem

StockNews.com began coverage on shares of CEL-SCI (NYSE:CVM – Free Report) in a report published on Thursday morning. The brokerage issued a sell rating on the stock.

CEL-SCI Trading Down 3.1 %

Shares of CVM opened at $0.25 on Thursday. The stock has a fifty day moving average of $0.26 and a two-hundred day moving average of $0.45. The company has a market capitalization of $20.76 million, a PE ratio of -0.51 and a beta of 0.50. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.09 and a current ratio of 1.07. CEL-SCI has a fifty-two week low of $0.18 and a fifty-two week high of $2.22.

Institutional Investors Weigh In On CEL-SCI

A hedge fund recently raised its stake in CEL-SCI stock. Thoroughbred Financial Services LLC boosted its stake in CEL-SCI Co. (NYSE:CVM – Free Report) by 40.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 191,661 shares of the company’s stock after buying an additional 54,900 shares during the quarter. Thoroughbred Financial Services LLC owned approximately 0.26% of CEL-SCI worth $76,000 at the end of the most recent quarter. Institutional investors own 12.08% of the company’s stock.

About CEL-SCI

(Get Free Report)

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.

Featured Stories